In current study, we found that tumor IDO1 expression was upregulated after NCT and was not observed distinct changes after NCRT in ESCC, which provided a theoretical basis for IDO1 inhibitors combined with traditional chemotherapy in ESCC. This evidence concerns the gene IDO1 and neoplasm.